New Bio-Identical HRT Option!

New Bio-Identical HRT Option!

Minivelle™ Estrogen Patch, Now Available In U.S. Pharmacies



Provides Effective Relief from Hot Flashes and Night Sweats Due to MenopauseDoctor with Patient

Noven Pharmaceuticals, Inc., the manufacturer of Vivelle-Dot® (estradioltransdermal system), today, January 31, 2013, announced the availability of Minivelle™ (estradiol transdermal system) by prescription in U.S. pharmacies. Last Fall the U.S. Food and Drug Administration (FDA) approved Minivelle™ for hot flashes and night sweats due to menopause.

Minivelle ™ is 34 percent smaller than Vivelle-Dot® and, at its lowest strength (0.0375 mg/day), has nearly the same surface area as a dime.

“Hot flashes and night sweats are the most commonly reported symptoms of menopause among women, said Mary Jane Minkin, M.D.,* clinical professor of obstetrics and gynecology at Yale University School of Medicine. “The availability of Minivelle™ in its unique size is significant as it offers women a discreet option to help manage these menopause symptoms.”

Since Minivelle™ is round with smooth, curved edges it may help prevent lifting or snagging associated with everyday wear.  Clinical studies show it has almost no sticky residue and causes almost no skin irritation.  Minivelle™ stays in place during bathing, exercising and everyday wear.

“The launch of Minivelle™ is an example of our commitment to providing innovative products tailored to women’s active and busy lifestyles, and adds to our growing portfolio – established more than 16 years ago – of treatment options for menopausal women,” said Jeffrey F. Eisenberg, Noven’s President and Chief Executive Officer.

About Minivelle™

Minivelle™ is indicated for the treatment of moderate to severe vasomotor symptoms due to menopause, commonly known as night sweats and hot flashes. At 2.48 cm2, the patch, at its lowest strength (0.0375 mg/day), has nearly the same surface area as a dime, making it the smallest estrogen therapy patch currently available. Minivelle™ has been approved with four dosing options – 0.0375 mg/day, 0.05 mg/day, 0.075 mg/day and 0.1 mg/day. Minivelle™ is manufactured by Noven Pharmaceuticals, Inc. (the manufacturer of Vivelle-Dot®), and is marketed and sold through the Women’s Health unit of Noven’s subsidiary, Noven Therapeutics, LLC.

Minivelle™ contains bioidentical estradiol, a plant-based estrogen that is chemically identical to the estrogen produced naturally by a woman’s body.

View drug information on Estradiol Transdermal SystemVivelleVivelle-Dot.

Related Posts


Share This